Please assess the completion status of the following clinical trial:

Trial Title: L-Glutamine Therapy for Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible to participate in the study, a patient must meet all of the following inclusion criteria:~* Patient is at least 18 years of age.~* Patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia (documented by hemoglobin electrophoresis).~* Patient has had at least two episodes of painful crises within 12 months of the screening visit.~* If the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the next 14 months.~* Patient or the patient's legally authorized representative has given written informed consent.~* If the patient is a female of child-bearing potential, she agrees to practice a recognized form of birth control during the course of the study.~* Patient is able to perform exercise tolerance test~Exclusion Criteria:~If the patient meets any of the following criteria, the patient must not be enrolled:~* Patient has a significant medical condition that required hospitalization (other than sickle painful crisis) within two months of the screening visit.~* Patient has diabetes mellitus with untreated fasting blood sugar \>115 mg/dL.~* Patient has prothrombin time International Normalized Ratio (INR) \> 2.0.~* Patient has serum albumin \< 3.0 g/dl.~* Patient has received any blood products within three weeks of the screening visit.~* Patient has a history of uncontrolled liver disease or renal insufficiency.~* Patient is pregnant or lactating.~* Patient has been treated with an experimental anti-sickling medication/treatment (except hydroxyurea) within 30 days of the screening visit.~* Patient has been treated with an experimental drug within 30 days of the screening visit.~* There are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-glutamine (Type: EXPERIMENTAL): L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily \>66.7 at 15 g 2X daily
- Placebo (Type: PLACEBO_COMPARATOR): Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily \>66.7 at 15 g 2X daily

Based on this trial design, predict the completion outcome and termination type (if applicable).